SCHEMBL6307443

SCHEMBL6307443

CCC(C)C(NC(=O)CO)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.53
FPR2 P25090 3/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
ATM Q13315 1/20 0.46
CA2 P00918 4/20 0.44
CA1 P00915 3/20 0.44
ENPEP Q07075 2/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MME P08473 1/20 0.42
ACE P12821 1/20 0.42
CPA1 P15085 1/20 0.42
ACE2 Q9BYF1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4186738 0.86 ALDH1A1 (0.63) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL4186736 0.86 ALDH1A1 (0.63) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL29048120 0.85 ALDH1A1 (0.58) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL29048118 0.85 ALDH1A1 (0.58) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL6307436 0.84 ALDH1A1 (0.61) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL23408841 0.82 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL935683 0.82 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL21274507 0.82 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL21274505 0.82 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL935682 0.82 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906058-B2 1,5-Benzothiazepines and their use as hypolipidaemics ASTRAZENECA AB (SE) 2005-06-14 US claimed
EP-1263747-B1 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS ASTRAZENECA AB (SE) 2004-11-24 EP claimed
US-20030166927-A1 1,5-Benzothiazepines and their use as hypolipidaemics ALBIREO AB (SE) 2003-09-04 US claimed
US-6906058-B2 1,5-Benzothiazepines and their use as hypolipidaemics ASTRAZENECA AB (SE) 2005-06-14 US disclosed
EP-1263747-B1 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS ASTRAZENECA AB (SE) 2004-11-24 EP disclosed
US-20030166927-A1 1,5-Benzothiazepines and their use as hypolipidaemics ALBIREO AB (SE) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166927-A1 1,5-Benzothiazepines and their use as hypolipidaemics SLC10A2, SLC10A1, LCAT ALDH1A1 811/4885L3MBTL1 999/4885FPR2 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.